References
Foster RH, Wagstaff AJ, Tetravalent human-rhesus reassortant rotavirus vaccine: a review of its immunogenicity, tolerability and protective efficacy against paediatric rotavirus gastroenteritis. BioDrugs 1998 Feb; 9(2): 155–78
Lanata CF, Midthun K, Black RE, et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996 Aug; 174: 268–75
Linhares AC, Gabbay YB, Mascarenhas JD, et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belém, Brazil. Bull World Health Organ 1996; 74: 491–500
Pérez-Schael I, Gutinas MJ, Pérez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997 Oct 23; 337(17): 1181–7
Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997 Oct; 131(4): 632–8
Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines — report of the National Multicenter Trial. Pediatrics 1996 Jan; 97: 7–13
Bernstein DI, Glass RI, Rodgers G, et al. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995 Apr 19; 273: 1191–6
Joensuu J, Koskenniemi E, Pang X-L, et al. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997 Oct 25; 350: 1205–9
Smith JC, Haddix AC, Teutsch SM. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics 1995 Oct; 96: 609–15
Griffiths RI, Anderson GF, Powe NR, et al. Economic impact of immunization against rotavirus gastroenteritis: evidence from a clinical trial. Arch Pediatr Adolesc Med 1995 Apr; 149: 407–14
Takala AK, Koskenniemi E, Joensuu J, et al. Economic evaluation of rotavirus vaccination in Finland [abstract no. 420]. Clin Infect Dis 1997 Aug; 25: 432
FDA advisory committee concludes that first vaccine for use in prevention of rotavirus gastroenteritis in infants is safe and effective [media release]. 1997 Dec 12; PR News wire; http://www.prnewswire.com
Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 1996; 174 Suppl. 1: S5–S11
Kapikian AZ, Chancock RM. Rotaviruses. In: Fields BN, Knipe DM, Howley PM, et al., editors. Fields virology. 3rd ed. v. 2. Philadelphia: Lippincott-Raven, 1996: 1657–705
Ceyhan M, Kanra G, Seçmeer G, et al. Take of rhesus-human reassortant tetravalent rotavirus vaccine in breast-fed infants. Acta Paediatr 1993 Mar; 82: 223–7
Rights and permissions
About this article
Cite this article
Rotavirus vaccine likely to reduce disease burden. Drugs Ther. Perspect 11, 1–5 (1998). https://doi.org/10.2165/00042310-199811090-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199811090-00001